Celldex Therapeutics

We're excited to welcome Meghan O'Neil, MS, CCRP to Celldex as our new Clinical Data Manager! From the lab bench to clinical trials coordination, Meghan adds valuable perspective to our team and we're excited to have her on board. She shares more below. 

We are pleased to present positive data on measurements of disease control and quality of life from the Phase 2 barzolvolimab studies in patients with chronic #urticaria. These data were presented by Dr. Martin Metz of Charité - Universitätsmedizin Berlin at #AAAAI25. Read more about this milestone for Celldex and patients living with CSU and CIndU here. https://lnkd.in/grnhwAPp

As we wrap up another year of innovation and growth at Celldex, we're grateful for the opportunity to reflect, appreciate our teammates and give back to our communities. We recently held holiday get-togethers and gift drives in our offices, which allowed us to donate a variety of items to help local families in need. Wishing you and yours a joyful holiday season. ❄️

Happy #Halloween! The Celldex team got into the spooky spirit with pumpkin carving by the water in our Fall River office. It's safe to say our creations turned out scary good. 🎃

This weekend, we presented positive results from the Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible #urticaria (CIndU), cold urticaria (ColdU) and symptomatic dermographism (SD), at #ACAAI24. This is the first therapy to demonstrate clinical benefit in patients with CIndU in a large, randomized placebo controlled study. CMO Diane Young shares her perspective on this promising milestone for Celldex below. Read more here. https://lnkd.in/e7GmFp-y

It felt like the perfect fall weather at our annual fall cornhole tournament and BBQ at our Fall River office last week! To complement the chilly yet sunny day, we had warm apple cider and apple crumble along with our traditional BBQ lunch. 🍁

It took over 3 years and the consult of multiple healthcare providers for Celldex Head of Medical Affairs Sukirti Bagal MD, MPH to receive her diagnosis of both chronic spontaneous urticaria (CSU) and cold urticaria (ColdU). In part two of her story, Suki takes us through her journey to diagnosis and the impact working at Celldex has had on her life. #UDAY2024

When Celldex Head of Medical Affairs Sukirti Bagal MD, MPH works with physicians and patients, she relates to them on a level many other professionals cannot: she, too, lives with chronic spontaneous #urticaria (CSU) and cold urticaria (ColdU) and understands on a personal level just how life-altering this disease can be. In honor of #UDAY2024, Suki shares her journey with urticaria. This is part one of her story.  

Tomorrow is #UDAY2024! Every member of the Celldex team, from research to human resources, is dedicated to advancing our mission of delivering new therapies for inflammatory diseases like #urticaria. We are getting ready to honor the millions affected by urticaria at Celldex tomorrow.

We are gearing up for #UDAY2024 next week. Each year, Urticaria Day aims to raise awareness of chronic #urticaria and advocate for new, improved treatment options for the millions of patients worldwide who live with this condition. We look forward to elevating the voices of team members, patients and healthcare providers next week in recognition of this life-altering disease. Learn more about #UDAY2024 from GA²LEN e.V., the Global Allergy and Asthma European Network.